IRF4 and BATF are critical for CD8(+) T-cell function following infection with LCMV. by Grusdat, M. et al.
OPEN
IRF4 and BATF are critical for CD8þ T-cell function
following infection with LCMV
M Grusdat1,8, DR McIlwain1,8, HC Xu1,2, VI Pozdeev1, J Knievel1, SQ Crome3, C Robert-Tissot3, RJ Dress4, AA Pandyra2, DE Speiser3,5,
E Lang1, SK Maney1, AR Elford3, SR Hamilton3, S Scheu4, K Pfeffer4, J Bode1, H-W Mittru¨cker6, M Lohoff7, M Huber7, D Ha¨ussinger1,
PS Ohashi3, TW Mak3, KS Lang2,8 and PA Lang*,1,8
CD8þ T-cell functions are critical for preventing chronic viral infections by eliminating infected cells. For healthy immune
responses, beneficial destruction of infected cells must be balanced against immunopathology resulting from collateral damage
to tissues. These processes are regulated by factors controlling CD8þ T-cell function, which are still incompletely understood.
Here, we show that the interferon regulatory factor 4 (IRF4) and its cooperating binding partner B-cell-activating transcription
factor (BATF) are necessary for sustained CD8þ T-cell effector function. Although Irf4–/– CD8þ T cells were initially capable of
proliferation, IRF4 deficiency resulted in limited CD8þ T-cell responses after infection with the lymphocytic choriomeningitis
virus. Consequently, Irf4–/– mice established chronic infections, but were protected from fatal immunopathology. Absence of
BATF also resulted in reduced CD8þ T-cell function, limited immunopathology, and promotion of viral persistence. These data
identify the transcription factors IRF4 and BATF as major regulators of antiviral cytotoxic T-cell immunity.
Cell Death and Differentiation (2014) 21, 1050–1060; doi:10.1038/cdd.2014.19; published online 14 February 2014
Chronic viral infections such as those involving the hepatitis C
virus and the human immunodeficiency virus (HIV) represent
a major global health burden.1,2 Control of viral infections
requires effective CD8þ T-cell responses to kill virus-infected
cells. However, destruction of infected cells in an attempt to
control viral replication can damage tissues and even result in
death. Identifying factors and mechanisms involved in
modulating cytotoxic T-cell functions is critical for providing
novel opportunities to treat chronic infections.
The interferon regulatory factor 4 (IRF4) is an important
immunological transcription factor required for B-cell matura-
tion3 and for the maintenance of various CD4þ T-cell subsets
including T helper (Th2),4,5 regulatory T cell,6 Th9,7, and
Th178 cells. However, the role of IRF4 in CD8þ T-cell
responses is less clear. IRF4 can influence the differentiation
of CD8þ T cells,9 including a subset that produces interleukin
(IL)-17.10 Cytotoxic responses towards the lymphocytic
choriomeningitis virus (LCMV) are also reduced during IRF4
deficiency,3 although it is unclear whether this defect is due to
CD8þ T cells or due to additional cell types. Very recently, it
has been reported that IRF4 is critical for CD8þ T-cell
responses to Listeria monocytogenes11 and for maintenance
of effector CD8þ T-cell function in response to the influenza
virus.12,13
IRF4 binds cooperatively with an activator protein-1 (AP-1)
family heterodimer consisting of B-cell-activating transcription
factor (BATF) and Jun-regulating gene expression in CD4þ
T cells during Th17 cell specification.14–16 Phenotypes for
BATF- and IRF4-deficient B and T cells are similar,17 and
there is emerging evidence that BATF is also necessary for
functional CD8þ T-cell responses. For instance, absence of
BATF results in fewer effector CD8þ T cells directed against
model antigen ovalbumin (OVA).18 However, the function of
BATF in an in vivo model of viral infection has not yet been
investigated, and its role during antiviral T-cell immunity
remains unclear.
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In this study, we found that IRF4 and BATF were
dispensable for initial T-cell proliferation but that absence of
IRF4 or BATF resulted in limited T-cell numbers and function
following infection with LCMV. Consequently, Irf4–/– mice
showed reduced immunopathology but were less able to
control viral replication. Consistently, BATF deficiency
resulted in limited immunopathology, reduced cytotoxic T-cell
immunity, and viral persistence after infection with LCMV.
Results
IRF4 deficiency inhibits T-cell-mediated hepatitis. We
first examined the response of wild-type (WT) and Irf4 /
mice to LCMV infection, which itself is not cytopathic, but
where liver damage occurs as a consequence of virus-
specific T-cell activity.19 Absence of IRF4 during infection
resulted in reduced quantities of virus-specific (gp33-tetþ )
CD8þ T cells relative to WT mice (Figure 1a). Consistently,
restimulation of splenocytes with LCMV peptides glycopro-
tein (gp33) or nucleoprotein (np396) resulted in less
activated interferon-g (IFN-g)-producing CD8þ T cells in
samples harvested from Irf4 / compared with WT animals
(Figure 1b). Control of LCMV largely depends on CD8þ
T cells to eliminate infected cells. Consistently, infectious
particles could be detected in the spleen, liver, lung, and
kidney tissue harvested from Irf4 / mice at 12 and 20 days
post infection, whereas significantly lower or undetectable
levels were present in organs from WT mice (Figure 1c).
During viral infections, activated CD8þ T cells can cause
collateral damage to tissues even during infections with
viruses possessing low levels of intrinsic cytotoxicity.1,2,20
Accordingly, in the model of LCMV used here, liver damage
is known to be driven by CD8þ T cells.19 Consistent with the
reduced presence of virus-specific and cytokine-producing
CD8þ T cells, infected Irf4 / mice were resistant to
infection-associated liver damage observed in WT mice by
release of the liver-specific enzyme alanine aminotransferase
(ALT) into the serum (Figure 1d). These effects may be
further explained by reduced lymphocyte infiltration seen in
hematoxylin and eosin-stained liver sections from infected
Irf4 / mice compared with Irf4þ /þ mice (Figure 1e). Thus,
the absence of IRF4 resulted in reduced CD8þ T-cell
function, limited control of viral replication, and resistance
to T-cell-mediated immunopathology in vivo.
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Figure 1 IRF4 deficiency impairs control of LCMV replication and prevents induction of T cell-mediated immunopathology. (a–e) Irf4þ /þor Irf4 / mice were infected
with 2 106 PFU LCMV-WE. (a) Proportion of gp33-H2-Db (gp33) and np396-H2-Db (np396) tetþ CD8þ T cells in single cell-suspended spleen tissue from WT and
IRF4-deficient mice 12 days after infection was analysed, and (b) Quantity of CD8þ T cells harvested 12 days after infection capable of producing IFN-g following in vitro
restimulation with gp33 or np396 is shown (flow cytometry; % of CD8þ cells; mean þ / S.E.M., n¼ 6 mice/group from two pooled experiments). (c) Virus titers were
determined in spleen, liver, lung, and kidney tissues on day 12 (D12) and 20 (D20) postinfection in WT and IRF4-deficient mice (mean±S.E.M., n¼ 5–7 mice/group). (d) Liver
damage was assessed by measuring ALT activity in the sera of WT and IRF4-deficient mice at different time points after infection as indicated (mean±S.E.M., n¼ 4
mice/group). (e) Snap-frozen liver sections from WT and IRF4-deficient animals were stained with hematoxylin and eosin. One representative image from n¼ 4 mice/group is
shown (scale bar, 200mm)
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IRF4-deficient T cells have defects during in vitro
culture. We next investigated whether defects would also
be present in IRF4-deficient CD8þ T cells cultured in vitro.
IRF4 protein expression in CD8þ T cells was strongly
upregulated by the presence of anti-CD3 antibodies in the
culture medium (Figure 2a). Although both WT and Irf4 /
CD8þ T cells actively proliferated following T-cell receptor
(TCR) stimulation in vitro (Figure 2b and Supplementary
Figure 1), fewer Irf4 / CD8þ T cells were observed
following 72 h of culture compared with WT (Figure 2c).
Relative to WT, Irf4 / CD8þ T cells were less able to
produce cytokines associated with effector function (IFN-g)
and survival (IL-2) (Figures 2d and e). Furthermore, a larger
proportion Irf4 / CD8þ T cells appeared to be undergoing
apoptosis based on elevated ceramide staining (Figure 2f)
and increased expression of activated caspase 3 (Figure 2g).
Active caspase 3 levels could be reduced in both genotypes
by the addition of the pan-caspase inhibitor Q-VD-OPh
(QVD) to the culture medium (Figure 2g). Consistently, a
lower percentage of viable cells (determined by annexin V
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Figure 2 CD8þ T cells from Irf4 / mice have defects in vitro. (a) Negatively sorted CD8þ T cells from WT mice were cultured for 96 h with 5mg/ml antiCD3. IRF4
expression was measured by intracellular staining and flow cytometry with mean fluorescence intensity (left)(mean±S.E.M.; n¼ 3, one out of two independent experiments
shown), and by western blot with actin loading control (right)(one representative of n¼ 3 experiments is shown). (b) Cells from Irf4þ /þ versus Irf4 / mice were stimulated
in vitro with, or without (control), 5 mg/ml antiCD3 and 2 mg/ml antiCD28 for 72 h and CFSE fluorescence was determined by flow cytometry. Representative histograms are
shown of n¼ 7. (c) Absolute cell count from b (mean þ / S.E.M.; n¼ 7). (d–h) Negatively sorted Irf4þ /þ versus Irf4 / T cells were stimulated with medium alone
(control) or 5mg/ml antiCD3 and 2 mg/ml antiCD28, plus Q-VD-OPh (QVD) where indicated, for 72 h in vitro. (d) Intracellular staining for IFN-g by flow cytometry is displayed
(mean±S.E.M., n¼ 6). (e) IL-2 concentration in conditioned media was measured by ELISA and mean±S.E.M. is illustrated (n¼ 6). (f) Cell surface ceramide staining was
assessed by flow cytometry (mean±S.E.M., n¼ 6). (g) Intracellular staining for active caspase 3 was determined by flow cytometry (mean±S.E.M., n¼ 6). (h) Cells were
exposed to AV and 7-AAD followed by analysis with flow cytometry. Representative dot plots (8000 events displayed/plot)(left) of n¼ 6 are shown, as well as % viable cells
(AV , 7-AAD , mean±S.E.M., n¼ 6, right)
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(AV) and 7-aminoactinomycin D (7-AAD) exclusion) was
observed in vitro in the absence of IRF4, an effect that could
be partially rescued by the addition of QVD (Figure 2h).
These data suggest that Irf4 / CD8þ T cells have defects
in vitro, including elevated apoptosis, which may be one
factor contributing to the reduced overall quantity of effector
CD8þ T cells observed in the IRF4-deficient setting.
IRF4 deficiency impacts response to low doses of
LCMV. In order to investigate the effects of IRF4 deficiency
on CD8þ T cells more closely, we next infected WT or Irf4 /
mice with a lower dose of LCMV, where substantial
quantities of virus-specific CD8þ T cells persisted in both
genotypes. Virus-specific CD8þ T cells were detected in
Irf4 / mice at 8 days post infection, although in lower levels
than in controls (for gp33-tetþ cells) (Figure 3a). Moreover,
CD8þ T cells isolated from both groups were capable of
producing IFN-g after restimulation with LCMV peptides gp33
or np396, but less cytokine production was observed in the
absence of IRF4 (Figure 3b). Even after adjusting for
differences in the number of virus-specific CD8þ T cells,
less cytotoxicity was observed on a per-cell basis in the
Irf4 / setting relative to the WT setting after LCMV
infection (Figure 3c). Interestingly, although cytotoxicity was
readily apparent in IRF4-deficient T cells 8 days after
infection, it appeared to be further reduced by day 10
(Supplementary Figure 2), suggesting that IRF4-deficient
T cells may exhibit progressive loss of T-cell functionality.
Furthermore, similar to our observations in vitro, a larger
proportion of virus-specific IRF4-deficient CD8þ T cells
appeared to be undergoing apoptosis compared with WT
controls based on AV and 7-AAD staining (Figure 3d).
IRF4-deficient CD8þ T cells fail to induce immuno-
pathology. In order to study the CD8þ T-cell-specific
effects of IRF4 without the potential influence of other T-cell
lineages, Irf4 / mice were first crossed onto the P14
transgenic background. P14 mice express a transgenic TCR
recognizing the LCMV gp33 epitope.21 Negatively sorted
CD8þ T cells from Irf4þ /þ or Irf4 / P14 transgenic TCR
mice were then transferred into recombination-activating
gene 1 (Rag1–/–) mice22 1 day before infection with a chronic
strain of LCMV (clone 13). Both Irf4þ /þ and Irf4 / P14
transfer resulted in expansion of virus-specific CD8þ
T cells measured in blood from recipients between 0 and 6
days post infection; however, fewer virus-specific T cells
were observed in the absence of IRF4 by days 4 and 6
(Figure 4a). Consistently, after restimulation with gp33, IFN-gþ
CD8þ T cells were seen to be markedly reduced on days
4 and 6 in blood samples from recipients of Irf4 /P14 cells,
compared with recipients of Irf4þ /þ P14 cells (Figure 4b).
Strong CD8þ T-cell responses can result in fatal immuno-
pathology after chronic LCMV infection;23 therefore, we
examined the survival of infected mice receiving either
transfer of Irf4þ /þ or Irf4 / P14 T cells. Recipients of
Irf4þ /þ P14 cells rapidly succumbed to severe immuno-
pathology withinB8 days, whereas recipients of Irf4 /P14
cells survived the length of the observation period
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Figure 3 Cytotoxic CD8þ T-cell responses to low-dose LCMV are impaired in the absence of IRF4 relative to controls. (a–d) Irf4þ /þor Irf4 / mice were infected with
200 PFU of LCMV-WE. (a) Percentage of gp33- and np396-tetþ CD8þ T cells in spleen tissue was measured 8 days after infection (% of CD8þ T cells, n¼ 4, one of three
independent experiments is shown). (b) Percentage of CD8þ T cells 8 days after infection capable of producing IFN-g after restimulation with virus-specific peptides gp33 or
np396 was measured by intracellular staining and flow cytometry (n¼ 8, pooled from three independent experiments). (c) Eight days after infection, splenocytes from WT and
IRF4-deficient mice were harvested and incubated with 51Cr labeled-EL-4 cells. Peptide-specific 51Cr release is shown in % for indicated effector/target ratios (gp33-tetþ
CD8þ cells/EL-4 cells)(mean±S.E.M., measured in duplicate, n¼ 4–5). (d) Cell viability was determined by ex vivo staining with AV (AV) and 7-AAD measured on gp33-
tetþ CD8þ T cells from spleen tissue of Irf4þ /þor Irf4 / mice 8 days post infection (mean±S.E.M., n¼ 4 mice/group)
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(Figure 4c). Thus, in this context, CD8þ T-cell-specific
defects limit the expansion of virus-specific cells and block
the induction of fatal immunopathology in the absence of
IRF4.
Impaired Irf4 / T-cell function results in limited
memory responses. We next investigated whether defects
in CD8þ T-cell responses observed in the absence of IRF4
would extend to the memory phase. Similar to observations
at earlier time points (Figures 1 and 3), at both 30 and 60
days following infection with LCMV, reduced quantities of
virus-specific (gp33-tetþ ) T cells were observed in the
spleen, bone marrow, and lymph nodes of IRF4-deficient
mice compared with WT animals (Figure 5a). At the same
time points, virus-specific CD8þ T cells from Irf4 / mice
had altered surface expression of CD27, CD44, CD62L,
interleukin-7 receptor, and killer cell lectin-like receptor
subfamily G member 1 (KLRG1) compared with cells from
Irf4þ /þ mice, with particularly low expression of KLRG1 in
the absence of IRF4 (Supplementary Figure 3). Restimula-
tion with the LCMV gp33 peptide in vitro resulted in robust
IFN-g, tumor necrosis factor-a, and IL-2 cytokine production
in CD8þ T cells isolated from Irf4þ /þ mice, but not from
Irf4 / mice, at both 30 and 60 days post infection
(Figure 5b). Next, we measured persistence of transferred
Irf4þ /þ versus Irf4 / P14 CD8þ T cells in WT mice
following LCMV infection. At both 30 and 60 days post
infection, massively reduced quantities of Irf4 / -trans-
ferred virus-specific T cells were detectable relative to
Irf4þ /þ controls (Figure 5c). Finally, we tested the ability of
transferred WT or IRF4-deficient P14 T cells to induce a
memory CD8þ T-cell immune response in WT animals
infected initially with LCMV and subsequently challenged
with a recombinant strain of Vaccinia virus expressing an
LCMV-GP.24 Following secondary challenge, mice receiving
WT P14 T cells displayed overt cytotoxicity to EL4 cells
coated with P14-specific peptides, whereas no cytotoxicity
was detected for mice receiving IRF4-deficient P14 T cells
(Figure 5d). Taken together, these data suggest that IRF4
deficiency results in reduced CD8þ effector function and
inability to produce normal CD8þ memory responses.
The IRF4 binding partner BATF is critical for control
of LCMV. IRF4 functionally cooperates with AP-1 transcrip-
tion factor heterodimer BATF–Jun in binding to composite
elements in T cells.15,17 Because BATF has been associated
with reduced T-cell immunity,18 we wondered whether mice
lacking BATF25 might have defects similar to IRF4-deficient
mice in controlling viral infection. Following TCR stimulation,
expression of BATF was strongly upregulated during in vitro
culture of WT CD8þ T cells (Figure 6a). WT and Batf /
CD8þ T cells displayed similar proliferative capacity in vitro
(Figures 6b and c and Supplementary Figure 4). However,
when BATF-deficient mice were challenged with low-dose
LCMV, reduced levels of virus-specific CD8þ T cells were
present compared with WT mice (Figure 6d). Consistently,
Batf–/– CD8þ T cells from infected mice also failed to
produce large quantities of IFN-g after stimulation with
LCMV peptides in sharp contrast to CD8þ T cells from WT
animals (Figure 6e). Similar to observations during IRF4
deficiency, a larger proportion of virus-specific BATF-
deficient CD8þ T cells appeared to be undergoing
apoptosis relative to cells harvested from WT animals
(Figure 6f). Consistent with impaired maintenance of a
normal population of virus-specific T cells, BATF-deficient
mice failed to control viral replication in the spleen, liver, and
lung tissue 8 days after infection, whereas virus was not
detectable in the organs of WT animals (Figure 6g).
Therefore, healthy immune responses to control LCMV
infection require BATF.
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Figure 4 Transferred Irf4 / CD8þ T cells fail to induce immunopathology.
(a–c) 3 106 negatively sorted CD8þ T cells from CD45.1þ Irf4þ /þP14 or
CD45.1þ Irf4 / P14 mice were transferred into Rag1–/– mice one day before
infection with 2 106 PFU LCMV clone13. (a) Quantity of transferred gp33
tetramer-specific CD8þ T cells was measured in the blood stream at indicated
days following infection (quantity/10ml blood, mean±S.E.M., n¼ 6–9 mice/group).
(b) Amount of IFN-gþCD8þCD45.1þT cells after restimulation with virus-specific
peptide gp33 was quantified (quantity/10ml blood, mean±S.E.M., n¼ 5–6
mice/group). (c) Survival of infected mice, which received negatively sorted Irf4þ /þ
versus Irf4 / P14 T cells was monitored overtime (n¼ 6 mice/group)
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BATF deficiency results in CD8þ T-cell-specific defects.
Next, we addressed whether the defects observed in BATF-
deficient animals might be connected to limited CD8þ T-cell
immunity. We therefore tested whether transfer of WT P14
T cells could rescue virus control in Batf–/– mice. When WT
virus-specific CD8þ P14 T cells were transferred into Batfþ /þ
or Batf–/– mice, they showed equivalent expansion and
ability to produce IFN-g after infection in both settings
(Figures 7a and b). Moreover, WT P14 transfer almost
entirely rescued defective virus control associated with the
absence of BATF (Figure 7c). These data suggested that
observed defects in viral control in the absence of BATF
were likely a consequence of reduced CD8þ T-cell function.
In order to more directly assess CD8þ T-cell function in the
absence of BATF, we crossed BATF mice with P14
transgenic TCR mice21 and performed a similar experiment
to that shown for IRF4 in Figure 4. Briefly, negatively sorted
CD8þ T cells from Batfþ /þ or Batf / P14 transgenic TCR
mice were transferred into Rag1–/– mice 1 day before
infection with a chronic strain of LCMV (clone 13). Both
transferred Batfþ /þ or Batf / P14 CD8þ T cells expanded
between 0 and 6 days post infection; however, in the
absence of BATF, less virus-specific cells were observed
on day 6 post infection (Figure 7d). Consistently, restimula-
tion with gp33 resulted in fewer IFN-g-producing cells in the
blood from recipients of Batf / compared with Batfþ /þ P14
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cells (Figure 7e). Similar to observations during IRF4
deficiency (Figure 4c), recipients of Batfþ /þ P14 cells rapidly
succumbed to severe immunopathology within B8 days,
whereas recipients of Batf / P14 cells survived the length
of the observation period (Figure 7f). Thus, BATF deficiency
appears to result in CD8þ T-cell intrinsic defects that block
the induction of fatal immunopathology.
Discussion
This study establishes an important role for both IRF4 and
BATF in the maintenance of CD8þ T-cell responses to LCMV.
After infection, both IRF4- and BATF-deficient mice showed
reduced quantities of virus-specific and cytokine-producing
T cells, and suffered from longer persistence of LCMV infections.
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Although IRF4-deficient mice were less able to control viral
replication, reduced CD8þ T-cell responses meant that,
during acute LCMV infection, IRF4-deficient mice were
protected from T-cell-driven hepatic immunopathology
(Figure 1). This effect appears to be CD8þ T-cell intrinsic,
and independent of defects in other T-cell lineages,4–8 as
transfer of P14 CD8þ T cells into Rag1 / mice (which
lack mature B and T cells) resulted in fatal LCMV immuno-
pathology in the presence, but not in the absence, of IRF4
(Figure 4). Thus, in this context, lacking IRF4 can protect
from toxic immunopathology, but at the expense of uncon-
trolled viral replication, which may be catastrophic in other
settings – for instance, those involving infection with cyto-
pathic viruses.
Consistent with our observations during LCMV infection,
recent reports further establish a necessity for IRF4 in effector
CD8þ T-cell functions towards L. monocytogenes and
influenza virus.11,12 Interestingly, although we observe that
initial expansion of IRF4-deficient T cells is evident both
in vitro and in vivo (Figures 2b and 4a), quantities of virus-
specific T cells are markedly reduced at later time points after
LCMV infection. Furthermore, there is a trend towards
declining cytotoxicity between days 8 and 10 following LCMV
infection, specifically in the IRF4-deficient setting (Figure 3c
and Supplementary Figure 2). These results suggest that
CD8þ effector function may progressively decline in the
absence of IRF4 and are consistent with observations of
progressive loss of CD8þ effector function after influenza
virus infection.12 Furthermore, in the absence of IRF4,
reduced CD8þ effector function remained evident at later
time points after LCMV infection, and cytotoxic recall
responses to a related secondary infection were blocked
(Figure 5). These data are also consistent with impaired
memory cell formation observed in the absence of IRF4 after
infection with L. moncytogenes.11
One potential mechanism contributing to reduced
CD8þ effector function that is supported by both our data
and two recent studies12,13 appears to be enhanced cell
death of Irf4 / virus-specific T cells (Figures 2f–h and 3d).
Similar to these studies, we observed that, in vitro,
IRF4-deficient T cells did not expand to the same degree
as WT controls, and displayed reduced viability
and elevated active caspase 3 staining consistent with
apoptosis.26 Cell death is a key mechanism limiting effector
T-cell responses,27 including following LCMV infection.28
However, the contribution of other potential factors to
limited CD8þ T-cell effector function, including abnormalities
in metabolic reprogramming,12 defects in effector T-cell
differentiation,13 or T cell exhaustion,29 warrants investigation
in future studies.
Elevated cell death may also occur in BATF-deficient
virus-specific CD8þ T cells (Figure 6f),13 suggesting that
similar defects might govern reduced CD8þ effector
function in both IRF4- and BATF-deficient mice. BATF
deficiency resulted in reduced ability to respond to
infection with LCMV and virus persistence (Figure 6).
These results are consistent with a reduction in CD8þ
effector T cells observed in BATF-deficient mice after
immunization with the model antigen OVA.18 Furthermore,
defects in viral control in Batf–/– mice could be overcome
by transfer of WT P14 CD8þ T cells (Figures 7a–c),
suggesting that inability to control LCMV infection in the
absence of BATF is likely due to problems in the CD8þ
T-cell compartment. Similar to observations during IRF4
deficiency (Figure 4), and in contrast to WT, absence of
BATF in transferred virus-specific CD8þ P14 T cells
precluded the induction of fatal T-cell immunopathology
following infection of Rag1 / mice (Figures 7d–f).
Therefore, BATF deficiency appears to result in T-cell
intrinsic defects that restrict effector function towards
LCMV. Interestingly, BATF may be relevant for exhaustion
of virus-specific CD8þ T cells during HIV infection in
humans.30 Future studies will aim to clarify how this function
relates to our observations and those of Kuroda et al.,18
which link absence of BATF to reduced CD8þ T-cell
function in mice.
Our results extend previous knowledge of the involvement
of IRF4 in the differentiation of certain CD8þ T-cell popula-
tions9,10 and indicate that IRF4-deficient cytotoxic CD8þ
T cells have an additional block in effector function evident
after LCMV infection. We observed similar defects in T-cell
immunity and virus control in the absence of either IRF4 or
BATF, suggesting that functional cooperation of BATF and
IRF4 reported for other T-cell subsets17 is likely also
necessary for normal CD8þ T-cell function. In conclusion,
we identified IRF4 and BATF to be critical regulators for CD8þ
T-cell function during viral infection. Mechanisms underlying
the control of these factors over CD8þ T-cell activity warrant
future investigation to uncover novel opportunities for ther-
apeutic intervention during treatment of chronic viral infections
in humans.
Materials and Methods
Mice, viruses, and virus titration. All mice used in this study
were maintained on a C57BL/6-J genetic background. IRF4-deficient, BATF-
deficient, P14, and Rag1-deficient mice have been previously described.3,21,25
Histological analysis of snap-frozen liver tissue was performed as previously
described.31 The LCMV-WE strain (originally obtained from F. Lehmann-Grube,
Heinrich Pette Institute, Hamburg, Germany), LCMV Clone13 (a gift from Sam
Basta, Queens University), and LCMV Armstrong (ARM) (provided by R.M.
Zinkernagel, University of Zurich) were propagated in L929 cells as previously
described.32 Virus titers were measured using a plaque-forming assay also as
previously described.32 Mice were infected intravenously with 200 or 2 106
plaque-forming units (PFU) LCMV-WE, 2 106 PFU LCMV clone13, or 2 103 or
2 105 PFU LCMV Armstrong. Following infection, ALT values in serum were
measured as previously described.33 All experiments were performed in single
ventilated cages. Animal experiments were carried out in accordance with the
guidelines of the Ontario Cancer Institute and the German law for animal
protection.
Purification of T cells. CD8þ or total T-cell populations were purified from
single cell-suspended splenocytes by negative selection following the manufac-
turer’s instructions (mouse CD8aþ T cell Isolation Kit II, mouse Pan T Cell
Isolation Kit II, Miltenyi, Bergisch Gladbach, Germany).
In vitro T-cell culture. Purified T cells were cultured in RPMI 1640 culture
medium (Biochrom, Berlin, Germany) with supplements (10% FCS, Biochrom) in
96-well flat-bottom tissue culture plates precoated with 5 mg/ml anti-CD3
(eBioscience, San Diego, CA, USA), 2mg/ml soluble anti-CD28 (BD Pharmingen,
Franklin Lakes, NJ, USA) (2 105 cells/well), and 10mM Q-VD-OPh hydrate
(Sigma, St. Louis, MO, USA) where indicated. Cells were cultured at 37 1C in a
humidified 5% CO2 incubator for 72 h. For proliferation analysis, isolated T cells
were labeled with 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester
(CFSE, Invitrogen, Carlsbad, CA, USA) for 10 min at 37 1C and washed twice with
culture medium.
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Transfer of P14 T cells. CD8þ T cells were isolated by negative selection
(mouse CD8aþ T cell Isolation Kit II,mouse Pan T Cell Isolation Kit II, Miltenyi)
from Irf4 / , Batf / , or P14 mice as indicated, and transferred (2 106 or
4 104 cells) i.v. 1 day before infection.
Flow cytometry analysis. Gp33-H-2Db and np396-H-2Db tetramer
production, surface and intracellular staining, and analysis by flow cytometry
were performed as previously described.34 AV-phycoerythrin was obtained from
Immunotools, Friesoythe, Germany, and 7-AAD from eBioscience. Anti-ceramide
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monoclonal antibodies (Enzo Life Sciences, Farmingdale, NY, USA) were used in
combination with fluorescein isothiocyanate (FITC) Goat anti-mouse IgG
(BD Pharmingen). Anti-CD3, anti-CD8, anti-IFN-g, anti-IRF4, anti-CD45.1, and
anti-CD45.2 were obtained from eBioscience. Intracellular staining with anti-
Caspase 3, active form FITC (BD Pharmingen) was performed using a FoxP3
staining kit (eBioscience).
Secondary challenge with Vaccinia-gp. C57BL/6 mice were injected
i.v. with 2 105 WT or Irf4 / P14 T cells 1 day before i.v. infection with 2000
PFU LCMV-ARM. After 254 days (8.5 months), mice were infected with 2 106
PFU of a LCMV-GP recombinant Vaccinia virus (Vaccina-gp) (provided by D
Bishop, Oxford University, Oxford, UK).24 Three days after infection with Vaccinia-gp,
mice were killed and splenocytes were used for cytotoxicity assays.
Cytotoxic lymphocyte assay. Analysis of cytotoxic capacity of mixed
splenocyte populations was conducted as previously described.34 Briefly, EL4
cells, pre-pulsed with gp33 or np396, or with MB6 (KAVVNIATM, P14-cell-
specific35) peptides, and preincubated with Cr51, were mixed with splenocytes at
indicated effector/target ratios. Cytotoxicity was determined by release of Cr51 into
the cell culture supernatant after 6 h.
Immunoblotting and ELISA. Immunoblotting was performed as previously
described31 using anti-IRF4 (Santa Cruz, Dallas, TX, USA), anti-BATF (Cell
Signaling, Beverly, MA, USA), and anti-b-Actin antibodies (Cell Signaling). IL-2
enzyme-linked immunosorbent assay (ELISA) was performed using cell-free
supernatants from conditioned T-cell medium and a mouse IL-2 ELISA Ready-
SET-Go! Kit following the manufacturer’s instructions (eBioscience).
Statistical analysis. Data are expressed as mean±S.E.M. Statistical
significance between two groups was analyzed using Student’s t-test. For
experiments involving analysis of multiple groups, two-way analysis of variance
with an additional Bonferroni post-test was used. The Mantel–Cox test was used
for analysis of survival curves. P-valueso0.05 were considered statistically
significant.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. We grateful for the technical assistance of Eugen
Ba¨cker and Stefanie Mu¨nch. This study was supported by the Alexander von
Humboldt Foundation (SKA2008 and SKA2010), the German Research Council
(SFB974, LA2558/3-1, LA2558/4-1, LA2558/5-1, TRR60, LA1419/5-1, SCHE692/3-1,
SCHE962/4-1), the Strategic Research Fund and VIVID graduate school of the
Heinrich-Heine-University and the NIH Tetramer Facility. SQC is a Banting Fellow.
ML was funded by the DZIF and the Behring-Ro¨ntgen-Stiftung. CRT is supported by
the Swiss National Science Foundation (PBZHP3_141467).
1. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus
infection. Nat Rev Immunol 2005; 5: 215–229.
2. Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nat Rev
Immunol 2013; 13: 487–498.
3. Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A et al.
Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte
function. Science 1997; 275: 540–543.
4. Lohoff M, Mittrucker HW, Prechtl S, Bischof S, Sommer F, Kock S et al. Dysregulated
T helper cell differentiation in the absence of interferon regulatory factor 4. Proc Natl Acad
Sci USA 2002; 99: 11808–11812.
5. Rengarajan J, Mowen KA, McBride KD, Smith ED, Singh H, Glimcher LH. Interferon
regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression.
J Exp Med 2002; 195: 1003–1012.
6. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT et al. Regulatory T-cell
suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature
2009; 458: 351–356.
7. Staudt V, Bothur E, Klein M, Lingnau K, Reuter S, Grebe N et al. Interferon-regulatory factor 4
is essential for the developmental program of T helper 9 cells. Immunity 2010; 33: 192–202.
8. Brustle A, Heink S, Huber M, Rosenplanter C, Stadelmann C, Yu P et al. The development
of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007; 8:
958–966.
9. Nayar R, Enos M, Prince A, Shin H, Hemmers S, Jiang JK et al. TCR signaling via Tec
kinase ITK and interferon regulatory factor 4 (IRF4) regulates CD8þ T-cell differentiation.
Proc Natl Acad Sci USA 2012; 109: E2794–E2802.
10. Huber M, Heink S, Pagenstecher A, Reinhard K, Ritter J, Visekruna A et al.
IL-17A secretion by CD8þ T cells supports Th17-mediated autoimmune encephalomyelitis.
J Clin Invest 2013; 123: 247–260.
11. Raczkowski F, Ritter J, Heesch K, Schumacher V, Guralnik A, Hocker L et al.
The transcription factor interferon regulatory factor 4 is required for the generation of
protective effector CD8þ T cells. Proc Natl Acad Sci USA 2013; 110: 15019–15024.
12. Man K, Miasari M, Shi W, Xin A, Henstridge DC, Preston S et al. The transcription factor
IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of
T cells. Nat Immunol 2013; 14: 1155–1165.
13. Yao S, Buzo BF, Pham D, Jiang L, Taparowsky EJ, Kaplan MH et al. Interferon regulatory
factor 4 sustains CD8(þ ) T cell expansion and effector differentiation. Immunity 2013; 39:
833–845.
14. Glasmacher E, Agrawal S, Chang AB, Murphy TL, Zeng W, Vander Lugt B et al.
A genomic regulatory element that directs assembly and function of immune-specific
AP-1-IRF complexes. Science 2012; 338: 975–980.
15. Li P, Spolski R, Liao W, Wang L, Murphy TL, Murphy KM et al. BATF-JUN is critical for
IRF4-mediated transcription in T cells. Nature 2012; 490: 543–546.
16. Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F et al. A validated regulatory
network for Th17 cell specification. Cell 2012; 151: 289–303.
17. Murphy TL, Tussiwand R, Murphy KM. Specificity through cooperation: BATF-IRF
interactions control immune-regulatory networks. Nat Rev Immunol 2013; 13: 499–509.
18. Kuroda S, Yamazaki M, Abe M, Sakimura K, Takayanagi H, Iwai Y. Basic leucine zipper
transcription factor, ATF-like (BATF) regulates epigenetically and energetically effector
CD8 T-cell differentiation via Sirt1 expression. Proc Natl Acad Sci USA 2011; 108:
14885–14889.
19. Zinkernagel RM, Haenseler E, Leist T, Cerny A, Hengartner H, Althage A. T cell-mediated
hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by
H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the
51Cr-release assay? J Exp Med 1986; 164: 1075–1092.
20. Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, Kurrer M et al. Aggravation of
viral hepatitis by platelet-derived serotonin. Nat Med 2008; 14: 756–761.
21. Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM. Tolerance induction in double
specific T-cell receptor transgenic mice varies with antigen. Nature 1989; 342: 559–561.
22. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-
deficient mice have no mature B and T lymphocytes. Cell 1992; 68: 869–877.
23. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH et al. Restoring function
in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682–687.
24. Hany M, Oehen S, Schulz M, Hengartner H, Mackett M, Bishop DH et al.
Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad
swelling reaction in mice by immunization with vaccinia-recombinant virus expressing
LCMV-WE nucleoprotein or glycoprotein. Eur J Immunol 1989; 19: 417–424.
25. Schraml BU, Hildner K, Ise W, Lee WL, Smith WA, Solomon B et al. The AP-1 transcription
factor Batf controls T(H)17 differentiation. Nature 2009; 460: 405–409.
26. McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring
Harb Perspect Biol 2013; 5: a008656.
Figure 7 Control of LCMV and induction of immunopathology depends on BATF expression in CD8þ T cells. (a–c) 2 105 splenocytes from WT CD45.1þP14 mice
were transferred into Batfþ /þ or Batf / mice one day before infection with 200 PFU LCMV-WE. (a) Quantity of gp33-tetþCD45.1þCD8þ T cells in spleen tissue from WT
and BATF-deficient animals 8 days after infection is shown (mean±S.E.M., n¼ 5 mice/group). (b) Amount of restimulated IFN-g producing CD45.1þCD8þ T cells in spleen
tissue from Batfþ /þ and Batf–/– mice 8 days after infection as measured following restimulation with the virus-specific peptide gp33 by intracellular staining and flow cytometry
is shown (mean±S.E.M., n¼ 5). (c) LCMV virus titers in spleen, liver, lung, and kidney tissues of infected Batfþ /þ or Batf / mice in the presence or absence of WT P14
transfer was measured (mean±S.E.M., n¼ 3–5 mice/group). (d–f) 3 106 negatively sorted CD8þ T cells from Batfþ /þ P14 or Batf / P14 mice were transferred on day
-1 into Rag1–/– mice followed by infection with 2 106 PFU of LCMV Clone13. (d) Quantity of transferred gp33-tetramerþ CD8þ T cells measured in the blood at indicated
days following infection is shown (quantity/10ml blood, mean±S.E.M., n¼ 4 mice/group). (e) Amount of IFN-gþCD8þ T cells after restimulation with the virus-specific
peptide gp33 was measured (quantity/10 ul blood, mean±S.E.M., n¼ 4 mice/group). (f) Survival of infected mice that received Batfþ /þ versus Batf / P14 T cells was
monitored over time (n¼ 4 mice/group)
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